ArticleThe AAPS journal2020
Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods.
Article in The AAPS journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology.Pharmaceutical research · 2025Review
- Physiologically Based Biopharmaceutics Modeling Coupled with Biopredictive Dissolution in Development of Bioequivalent Formulation for Mesalamine Enteric Coated Tablet: A Tough Nut to Crack.AAPS PharmSciTech · 2024Article
- A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and extended-release capsule.CPT: pharmacometrics & systems pharmacology · 2024Article
- Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products.Journal of pharmacokinetics and pharmacodynamics · 2023Article
- Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib.Pharmaceutics · 2021Article
- Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.The AAPS journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Different approaches based on deconvolution and convolution analyses have been proposed to establish IVIVC. A new implementation of the convolution-based model was used to evaluate the time-scaled IVIVC using the convolution (method 1) and the deconvolution-based (method 2) approaches. With the deconvolution-based approach, time-scaling was detected and estimated using Levy's plots while with the convolution-based approach, time-scaling was directly determined by a time-scaling sub-model of the convolution integral model by nonlinear regression. The objectives of this study were (i) to show how time-scaled deconvolution and convolution-based approaches can be implemented using population modeling approach using standard nonlinear mixed-effect modeling software such as NONMEM and R, and (ii) to compare the performances of the two methods for assessing IVIVC using complex in vivo drug release process. The impact of different PK scenarios (linear and nonlinear PK disposition models, and increasing levels of inter-individual variability (IIV) on in vivo drug release process) was considered. The performances of the methods were assessed by computing the prediction error (%PE) on C
Indexed as
Identifiers
32297044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.